Lexicon Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
LXRX Nasdaq 2836 www.lexpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Lexicon Pharmaceuticals, Inc.

Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain - Jan 21st, 2025 1:00 pm
Here’s Why Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Is Among the Best Diabetes Stocks to Buy Under $10 - Jan 6th, 2025 2:16 pm
Lexicon Appoints Scott Coiante as Chief Financial Officer - Jan 2nd, 2025 1:00 pm
Private equity firms account for 47% of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) ownership, while institutions account for 33% - Dec 30th, 2024 1:07 pm
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin) - Dec 20th, 2024 9:30 pm
Lexicon completes subject enrolment for DPNP trial of LX9211 - Nov 27th, 2024 12:30 pm
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) - Nov 26th, 2024 1:00 pm
Lexicon Pharmaceuticals to Participate in December Investor Conferences - Nov 25th, 2024 9:15 pm
Lexicon Pharmaceuticals to Cut 60% of Workforce - Nov 22nd, 2024 1:43 pm
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA - Nov 22nd, 2024 12:32 pm
Lexicon to disband sales team, lay off 60% of staff - Nov 22nd, 2024 10:05 am
Lexicon Appoints Ivan H. Cheung to Board of Directors - Nov 20th, 2024 9:05 pm
Lexicon Pharmaceuticals (NASDAQ:LXRX investor three-year losses grow to 80% as the stock sheds US$107m this past week - Nov 18th, 2024 1:07 pm
Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association’s (AHA) Sessions 2024 in Chicago - Nov 14th, 2024 1:00 pm
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... - Nov 13th, 2024 7:20 am
Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Lags Revenue Estimates - Nov 12th, 2024 10:25 pm
Lexicon: Q3 Earnings Snapshot - Nov 12th, 2024 9:25 pm
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - Nov 12th, 2024 9:05 pm
Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference - Nov 6th, 2024 1:00 pm
A diabetes drug, twice rejected, stumbles again — but its developer persists - Nov 6th, 2024 7:58 am